trending Market Intelligence /marketintelligence/en/news-insights/trending/jV-nar_IfDYicjnOfiHybw2 content esgSubNav
In This List

US FDA accepts Sun Pharma application for eye treatment

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


US FDA accepts Sun Pharma application for eye treatment

Sun Pharmaceutical Industries Ltd. said the U.S. Food and Drug Administration accepted its new drug application for Seciera, a treatment for the dry eye disease.

The treatment, a clear aqueous solution, is now under review for approval by the regulator.

Once approved, Sun Pharma plans to commercialize Seciera in the U.S. through its subsidiary Sun Ophthalmics Inc.

Seciera, also known as OTX-101, previously met its main and secondary goals in a phase 3 trial in patients with the disease.